French Sanofi buys American Provention Bio for 2,900 million dollars

French Sanofi buys American Provention Bio for 2,900 million dollars

FILE PHOTO: A logo on the Sanofi exhibition space during the Viva Technology conference dedicated to innovation and start-ups at the Porte de Versailles exhibition center in Paris, France June 15, 2022. REUTERS / Benoit Tessier

By Dina Kartit

March 13 (Reuters) – France’s Sanofi said on Monday it had reached an agreement to acquire U.S. biopharmaceutical company Provention Bio in a deal valued at $2.9 billion, or $25 per share in cash.

With this acquisition, the French pharmaceutical group intends to acquire full ownership of an innovative treatment to delay stage 3 type 1 diabetes, which affects some 65,000 people each year, according to a press release.

TZIELD (teplizumab-mzwv), approved in the United States last year, is the first and only drug indicated to delay the onset of type 1 stage 3 diabetes in adults and pediatric patients 8 years of age and older with type 1 to stage 2 diabetes.

Sanofi said it expects to complete the acquisition in the second quarter of 2023.

(Reporting by Dina Kartit; Editing by Kim Coghill; Editing in Spanish by Tomás Cobos)

Melissa Galbraith
Melissa Galbraith is the World News reporter for Globe Live Media. She covers all the major events happening around the World. From Europe to Americas, from Asia to Antarctica, Melissa covers it all. Never miss another Major World Event by bookmarking her author page right here.For tips or news submission: